Bone News and Research

RSS

80-unit patient housing facility for cancer patients and families

The SCCA House, an 80-unit patient housing facility for cancer patients and their families and caregivers, was dedicated today during ceremonies at its South Lake Union location. The facility is the second such "home away from home" building that is operated by the Seattle Cancer Care Alliance. Rooms are scheduled to be available to SCCA patients by the end of the month.

18 Sep 2009

Drug carrier that cuts off blood supply to tumors

To that end, Dr. Ronit Satchi-Fainaro of Tel Aviv University's Department of Physiology and Pharmacology, Sackler School of Medicine, and her team of researchers have developed a new drug carrier to deliver compounds straight to the tumor.

18 Sep 2009

Vitamin K prevents age-related conditions

An important analysis conducted by Children's Hospital Oakland Research Institute scientists suggests the importance of ensuring optimal dietary intakes of vitamin K to prevent age-related conditions such as bone fragility, arterial and kidney calcification, cardiovascular disease, and possibly cancer. Vitamin K is concentrated in dark green plants such as spinach or Swiss chard, and is either not present or present in only small amounts in most multivitamin pills.

18 Sep 2009

Rising trend in youth sports-related injuries

Thirty million children and teens are busy gearing up for the fall athletic season. What they're not gearing up for is a sprained, strained or fractured ankle. However, US Consumer Product Safety Commission statistics reveal 3.5 million children and teens get hurt annually playing organized and/or school sports.

18 Sep 2009

Quidel's QuickVue Influenza A+B test receives special 510(k) clearance for H1N1 reactivity update

Quidel Corporation (NASDAQ: QDEL), a global leader in point-of-care (POC) rapid diagnostic tests, received Special 510(k) clearance for an update to the Company's QuickVue® Influenza A+B test package insert to include reactivity with culture isolates of the 2009 H1N1 Influenza A virus.

17 Sep 2009

Enzo expands its capability to perform simultaneous live-cell imaging of nuclear components

Enzo Life Sciences, a division of Enzo Biochem, Inc. (NYSE:ENZ), has added a novel new system to its CELLestial™ line of live cell analysis products, providing expanded capability to simultaneously image both the nucleus and the nucleolus in living cells, the Company announced today. Called the Total Nuclear-ID™ Green/Red Nucleolar/Nuclear Detection Kit, the new addition has been specifically optimized for demanding live cell microscopy applications.

17 Sep 2009

Mayo Clinic Health Letter discusses kidney stone treatment options

Ordinary, loud snoring doesn't seem to be harmful, according to the September issue of Mayo Clinic Health Letter. But snorers still may want to seek treatment to stop snoring, reduce embarrassment and improve sleep for themselves and their bed partner.

17 Sep 2009

Bayer HealthCare to present its clinical trial data at a joint Multidisciplinary Congress

Bayer HealthCare today announced that data from more than 30 clinical trials evaluating three products in the company's oncology portfolio - Nexavar(R) (sorafenib) tablets, regorafenib (BAY 73-4506) and Alpharadin(TM) - will be presented at the joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress, September 20-24, 2009 in Berlin, Germany.

17 Sep 2009

Charley's Fund and the Nash Avery Foundation to support investigation of Galapagos' SARM candidate drug

Galapagos NV (Euronext: GLPG), Charley's Fund Inc. and the Nash Avery Foundation announced today that they will collaborate to investigate the potential effectiveness of Galapagos' SARM candidate drug, G100192, in treating Duchenne muscular dystrophy. G100192 is an orally-available small molecule therapeutic, which has demonstrated successful Proof of Concept in pre-clinical studies for cachexia (the loss of weight and muscle mass).

17 Sep 2009

Findings may lead to drugs that destroy TB in dormant stage of lifecycle

Attempts to eradicate tuberculosis (TB) are stymied by the fact that the disease-causing bacteria have a sophisticated mechanism for surviving dormant in infected cells. Now, a team of scientists led by researchers from Weill Cornell Medical College has identified compounds that inhibit that mechanism -- without damaging human cells.

17 Sep 2009

SI-BONE's summit to develop clinical diagnostic process for SI Joint pathology identification

SI-BONE, Inc. a San Francisco Bay-area, medical device company, announced the first ever meeting of thought leading spine surgeons to review data and develop a clinical diagnostic process for identification of SI Joint pathology, a frequent cause of low back pain.

17 Sep 2009

DNage's observational study assesses natural progression of CS in children

Biotech company Pharming Group NV ("Pharming" or "the Company") announced today that its wholly-owned subsidiary DNage has initiated an observational study in children suffering from Cockayne Syndrome (CS).

17 Sep 2009

Genentech releases Phase III PRIMA study findings

Genentech, Inc., a wholly-owned member of the Roche Group and Biogen Idec, today announced that a Phase III study (PRIMA) showed that patients with follicular lymphoma who continued receiving Rituxan (rituximab) alone after responding to Rituxan and chemotherapy lived longer without their disease worsening (progression-free survival or PFS) than those who did not continue to receive Rituxan.

17 Sep 2009

Successful eye surgery involves eyetooth implant in eye

Blind for nine years, Sharron “Kay” Thornton has just regained her sight through a first-in-the-U.S. surgical procedure at Bascom Palmer Eye Institute at the University of Miami Miller School of Medicine. The procedure -- modified osteo-odonto-keratoprosthesis (MOOKP) -- implanted her eyetooth in her eye, as a base to hold a prosthetic lens.

17 Sep 2009

Clinical trial focuses on healing diabetic foot ulcers with stem cells

Fortis Healthcare, one of India's leading private hospital groups, has announced it will broaden inclusion criteria for its upcoming diabetic foot clinical trial. The study will use stem cells derived from peripheral blood to treat critical limb ischemia (diabetic foot).

17 Sep 2009

Study: Antiretroviral drugs may prevent HIV infection in women

Hopeful that some of the same antiretroviral (ARV) drugs used to treat HIV infection can also prevent it, researchers from the Microbicide Trials Network have enrolled the first participants into a new, large-scale clinical trial testing two approaches of the strategy in women.

17 Sep 2009

Green tea may help prevent cancer and bone loss

Researchers in Hong Kong are reporting new evidence that green tea - one of the most popular beverages consumed worldwide and now available as a dietary supplement - may help improve bone health.

17 Sep 2009

New intraoperative nerve integrity monitors from Medtronic

Medtronic (NYSE: MDT) recently announced the launch of the NIM-Response® 3.0 and NIM-Neuro® 3.0 intraoperative nerve integrity monitors designed for a variety of surgeons, including ear, nose, and throat (ENT); endocrine; general; and peripheral surgeons.

17 Sep 2009

VOICE clinical study for testing the efficacy of two HIV prevention strategies

A new, large-scale clinical trial is examining whether antiretroviral medications normally used to treat HIV infection can also prevent HIV infection in women when applied as a vaginal gel or taken as oral tablets once daily.

16 Sep 2009

Amgen to present its four Phase 3 clinical trial results

Amgen today announced it will present detailed data from four Phase 3 studies as well as other data at the ECCO 15 - ESMO 34 European Multidisciplinary Congress, September 20 - 24, 2009 in Berlin, Germany.

16 Sep 2009